In Wednesday’s Wall Street session, Moleculin Biotech Inc (NASDAQ:MBRX) shares traded at $0.57, up 9.70% from the previous session.
MBRX stock price is now -23.19% away from the 50-day moving average and -63.06% away from the 200-day moving average. The market capitalization of the company currently stands at $13.78M.
, while ‘Oppenheimer’ rates the stock as ‘Outperform’
In other news, Foster Jonathan P., Chief Financial Officer bought 270,270 shares of the company’s stock on Jun 23 ’25. The stock was bought for $100,000 at an average price of $0.37. Upon completion of the transaction, the Chief Financial Officer now directly owns 287,587 shares in the company, valued at $0.16 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 23 ’25, CEO and President KLEMP WALTER V bought 675,675 shares of the business’s stock. A total of $250,000 was incurred on buying the stock at an average price of $0.37. This leaves the insider owning 743,607 shares of the company worth $0.42 million. A total of 8.74% of the company’s stock is owned by insiders.
During the past 12 months, Moleculin Biotech Inc has had a low of $0.25 and a high of $4.71. As of last week, the company has a debt-to-equity ratio of 11.25, a current ratio of 1.35, and a quick ratio of 1.35. The fifty day moving average price for MBRX is $0.74476 and a two-hundred day moving average price translates $1.54857 for the stock.
The latest earnings results from Moleculin Biotech Inc (NASDAQ: MBRX) was released for 2025-03-31.
